Accord Healthcare

What Accord Healthcare does

Accord Healthcare, Inc. is the US operating subsidiary of India-based Intas Pharmaceuticals Ltd., headquartered in Raleigh/Durham, North Carolina. The company develops, manufactures, and markets FDA-approved generic pharmaceutical products across oncology, cardiovascular, central nervous system, immunology, women's health, and infectious disease therapeutic areas. Its portfolio spans a full range of dosage forms including oral solids, topicals, liquids, lyophilized injectables, and complex injectables, with particular strength in oncology where it holds a 30% volume share of major chemotherapy injectable molecules and is ranked among the top 10 generic players by US prescription volume (IQVIA NSP MAT April 2022).

Manufacturing is vertically integrated under parent Intas Pharmaceuticals, leveraging three FDA-approved facilities in Ahmedabad, India (Matoda and SEZ), supported by 500 scientists across global R&D operations. Accord has completed 130 manufacturing facility inspections over the past 10 years, including 22 US FDA inspections, evidencing strong regulatory and quality systems. The business has expanded beyond generics into biosimilars through its Accord BioPharma division, with a stated ambition to launch 20 biosimilars by 2030, and into plasma-derived medicines through its Accord Plasma subsidiary following the October 2025 acquisition of Prothya Biosolutions Belgium BV.

Commercial operations in the US rely on exclusive wholesale distribution agreements with Cardinal Health, Cencora, McKesson, and Morris & Dickson for national reach to hospitals, integrated delivery networks, oncology clinics, retail pharmacies, and group purchasing organizations. Recent product launches include Lenalidomide Capsules (Feb 2026), Tadalafil Tablets (May 2026), Hydrochlorothiazide Tablets (Apr 2026), and biosimilars HERCESSI (trastuzumab-strf), IMULDOSA (ustekinumab-srlf), and Denosumab biosimilars OSVYRTI and JUBEREQ. The company has secured preferred formulary status for key biosimilars with Cigna and Express Scripts. Revenue model is unit-based generic and biosimilar drug sales through wholesale distribution, with pricing determined by dosage form, strength, and contract terms negotiated with GPOs and health systems. US annual sales stand at $668M.

Name

Accord Healthcare

Legal name

Accord Healthcare, Inc.

Website

https://accordhealthcare.us

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

101–250 employees

Short description

Accord Healthcare is the US subsidiary of India's Intas Pharmaceuticals, developing and marketing FDA-approved generic and biosimilar pharmaceuticals across oncology, immunology, CNS, and cardiovascular areas, distributed through Cardinal, Cencora, McKesson, and Morris & Dickson to hospitals, health systems, and pharmacies.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Generic pharmaceuticals
• Oncology injectables
• Biosimilars manufacturing
• Complex generics
• FDA-approved medications

Headquarters

HQ city

Raleigh

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Sales: Accord Healthcare generates revenue through the sale of FDA-approved generic pharmaceutical products including oral medications, injectables, and topical treatments. Products are distributed through wholesale distribution partners and directly to healthcare providers. Revenue is derived from one-time product transactions with recurring customer relationships.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Accord Healthcare develops, manufactures, and markets FDA-approved generic pharmaceutical products across multiple therapeutic areas including oncology, cardiovascular, central nervous system, immunology, and infectious diseases. Its portfolio spans orals, topicals, liquids, lyophilized and complex injectables, with a leadership position in oncology (30% volume share of major chemotherapy injectable molecules). The company also develops biosimilars through Accord BioPharma and plasma-derived medicines through Accord Plasma B.V., distributing through major pharmaceutical wholesalers to hospitals, oncology clinics, and retail pharmacies.

Product overview

Accord Healthcare is a generic and specialty pharmaceutical company that provides affordable, essential medicines through its portfolio of FDA-approved generic drugs. The company operates as the US subsidiary of Intas Pharmaceuticals and markets products across multiple therapeutic areas including oncology, cardiovascular, central nervous system, immunology, and infectious diseases. The portfolio consists primarily of oral tablets and capsules, injectable chemotherapy agents, and specialty medications, with particular strength in oncology where Accord holds significant volume share of major chemotherapy injectable molecules. Products are distributed through major pharmaceutical distributors including Cardinal, Cencora, McKesson, and Morris & Dickson. The company has three FDA-approved manufacturing facilities in India and is among the top 10 generic players by prescription volume in the US.

Differentiator

Problem solved

Functional benefit

Brands

• Accord BioPharma: A division of Accord Healthcare developing and commercializing innovative therapies across oncology, immunology, urology, and women's health, with one of the industry's most robust biosimilar pipelines.
• Accord Plasma
• Osvyrti
• Jubereq

Products and services

• Lenalidomide Capsules Generic version of Revlimid for treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. Available in 2.5mg, 5mg, 10mg, 15mg, 20mg, and 25mg strengths. Subject to REMS program.
• Anastrozole Tablets Generic version of Arimidex indicated for the treatment of breast cancer in postmenopausal women. Available in 1mg strength in 30ct, 90ct, and 500ct pack sizes.
• Atropine Sulfate Injection
• Azacitidine Injection
• Bicalutamide Tablets
• Buprenorphine-Naloxone SL Tablets
• Bupropion Extended Release Tablets
• Busulfan Injection
• Capecitabine Tablets
• Carboplatin Injection
• Cisplatin Injection
• Clomiphene Citrate Tablets Generic version of Clomid for treatment of ovulatory dysfunction in women desiring pregnancy. Available in 50mg strength in 10ct and 30ct blister packs.
• Clonazepam Tablets
• Dehydrated Alcohol Injection (Ablysinol)
• Dalfampridine Extended Release Tablets
• Denosumab Biosimilars (Osvyrti and Jubereq) Biosimilar denosumab medicines for bone health indications including osteoporosis and bone metastases, available under Accord BioPharma. Part of Accord's biosimilar portfolio with goal of introducing 20 biosimilars by 2030.
• Etoposide Injection
• Eplerenone Tablets
• Hydrochlorothiazide Tablets Diuretic for treatment of hypertension and edema associated with congestive heart failure and other conditions. Available in 12.5mg, 25mg, and 50mg strengths in 100ct and 1000ct packs.
• Hydroxychloroquine Tablets
• Carbidopa and Levodopa ER Tablets
• Letrozole Tablets
• Levothyroxine Tablets
• Methotrexate Injection
• Methotrexate Tablets
• Methylphenidate IR Tablets
• Mycophenolate Capsules
• Mycophenolic Acid DR Tablets
• Naltrexone Hydrochloride Tablets
• Quetiapine Fumarate ER Tablets
• Tadalafil Tablets Generic PDE5 inhibitor for treatment of erectile dysfunction, benign prostatic hyperplasia, and combination of both. Available in 2.5mg, 5mg, 10mg, and 20mg strengths in 30ct and 500ct packs.
• Temozolomide Capsules
• Temsirolimus Injection
• Topotecan Hydrochloride Injection
• Topotecan Injection (RTU)

Quantifiable outcome

• 30% volume share of major chemotherapy injectable molecules
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered minor, core and regional.

• Purdue PharmaminorOthers · 1 April 2026Generic-drug maker Accord Healthcare Inc. involved in Federal Circuit proceedings regarding oxycodone formulation patent invalidation dispute with Purdue Pharma.
• Foresee PharmaceuticalscoreGTM or Marketing Partner · 6 March 2026Exclusive licensing agreement for European commercialization of CAMCEVI 21mg, a 3-month formulation for advanced prostate cancer treatment. Accord Healthcare received exclusive rights to commercialize the product across Europe following CHMP positive opinion recommending approval.
• Kashiv BioSciencescoreStrategic or Co-development Partner · 10 February 2026Exclusive licensing and supply agreement for a complex peptide product covering pan-European, UK, and India markets. Kashiv handles regulatory registration and manufacturing while Intas and Accord Healthcare manage commercialization and distribution.
• ImmunityBiocoreStrategic or Co-development Partner · 1 February 2026Partnership to expand European access to ANKTIVA across 33 countries. Accord Healthcare deployed an 85-person sales force across 30 countries in the UK, EU, and EFTA to commercialize the bladder cancer drug. European Commission authorized ANKTIVA in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer.
• Arabian EthicalsregionalGTM or Marketing Partner · 1 December 2025Partnership to enhance availability of cancer therapies and oncology treatments across the UAE market, expanding patient access in the Middle East region.
• ZentivaminorOthers · 1 December 2025Generics company that filed counterclaims for revocation alongside Accord Healthcare against Sanofi's European Patent EP 466 covering cabazitaxel (Jevtana) cancer drug.
• StadaminorOthers · 1 December 2025Generics company that filed counterclaims for revocation alongside Accord Healthcare against Sanofi's European Patent EP 466 covering cabazitaxel (Jevtana) cancer drug.
• Dr. Reddy's LaboratoriesminorOthers · 1 December 2025Generics company that filed counterclaims for revocation alongside Accord Healthcare against Sanofi's European Patent EP 466 covering cabazitaxel (Jevtana) cancer drug.
• Prothya BiosolutionscoreStrategic or Co-development Partner · 1 October 2025Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, acquired Prothya Biosolutions Belgium BV and its subsidiaries to expand global plasma therapy capabilities. The acquisition strengthens access to plasma-derived medicines and increases manufacturing capacity for treating conditions such as immune deficiencies and hemophilia.
• Intas PharmaceuticalscoreStrategic or Co-development Partner · 1 August 2025Intas Pharmaceuticals partnered with Accord Healthcare to acquire the Udenyca product line from Coherus Biosciences, aiming to form one of the world's largest pegfilgrastim suppliers.

Scale indicators6 records

Recent moves4 records

Expansion highlights6 records

Direct peers

• Zydus Pharmaceuticals (Cadila): Indian pharmaceutical company with US generics business focused on injectables, transdermals, and biosimilars. Comparable to Accord as vertically integrated Indian generic manufacturer with US injectable franchise and biosimilar ambitions.
• Aurobindo Pharma: Indian generic pharmaceutical manufacturer with major US operations through AuroMedics, focused on injectable and oral generics. Comparable to Accord in vertically integrated Indian manufacturing, US injectable focus, and biosimilar development.
• Hikma Pharmaceuticals: Jordan-headquartered generic pharmaceutical company with significant US injectable portfolio. Comparable to Accord in US generic injectable focus, complex generic manufacturing capabilities, and biosimilar entry strategy.
• Apotex: Canadian-headquartered generic pharmaceutical manufacturer with US operations focused on generic injectables and biosimilars through Apobiologix. Comparable to Accord in complex generics, biosimilar development, and US distribution through major wholesalers.
• Dr. Reddy's Laboratories: Indian-headquartered generic pharmaceutical company with US operations focused on generic injectables, oncology, and biosimilars. Highly comparable to Accord given shared Indian manufacturing base, US generic injectable focus, and active patent litigation strategy.
• Lupin Pharmaceuticals: Indian-headquartered generic pharmaceutical company with US operations focused on orals, injectables, and complex generics. Comparable to Accord in generic injectables, Indian manufacturing base, and biosimilar pipeline development.
• Sun Pharmaceutical Industries: Largest Indian pharmaceutical company with significant US generic presence through Caraco and Taro. Directly comparable to Accord as Indian-headquartered generic competitor with US sales focus and oncology injectable portfolio.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with extensive US portfolio across orals, injectables, and biosimilars. Directly comparable to Accord as a broad-based generic competitor with significant US market share and oncology injectable presence.
• Sandoz (Novartis): Global generic and biosimilar leader spun out from Novartis, with major US generic injectable portfolio and biosimilar pipeline. Comparable to Accord in the generic injectable and biosimilar oncology space with broader geographic reach.
• Viatris: Major global generics company formed from Mylan-Upjohn combination with substantial US generic, biosimilar, and specialty portfolio. Closely comparable to Accord in generic injectables, biosimilars, and broad therapeutic area coverage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/accord-healthcare-us

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accord Healthcare